

Jack A Schalken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1568922/publications.pdf>

Version: 2024-02-01

457
papers

22,556
citations

8159

76
h-index

12233

133
g-index

476
all docs

476
docs citations

476
times ranked

19937
citing authors

#	ARTICLE	IF	CITATIONS
1	DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. <i>Cancer Research</i> , 1999, 59, 5975-9.	0.4	803
2	DD3/PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer. <i>European Urology</i> , 2003, 44, 8-16.	0.9	603
3	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009, 41, 221-227.	9.4	572
4	DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. <i>Cancer Research</i> , 2002, 62, 2695-8.	0.4	484
5	Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. <i>Cancer Research</i> , 1992, 52, 5104-9.	0.4	450
6	Allelic loss of chromosomes 16q and 10q in human prostate cancer.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 8751-8755.	3.3	436
7	Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. <i>Urology</i> , 2005, 66, 35-63.	0.5	398
8	Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy. <i>European Urology</i> , 2008, 54, 1081-1088.	0.9	394
9	Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. <i>Cancer Research</i> , 1994, 54, 3929-33.	0.4	383
10	Prevention and early detection of prostate cancer. <i>Lancet Oncology</i> , The, 2014, 15, e484-e492.	5.1	372
11	Cadherin switching in human prostate cancer progression. <i>Cancer Research</i> , 2000, 60, 3650-4.	0.4	345
12	Androgen receptors in endocrine-therapy-resistant human prostate cancer. <i>International Journal of Cancer</i> , 1991, 48, 189-193.	2.3	341
13	ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. <i>European Urology</i> , 2009, 56, 275-286.	0.9	332
14	Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5103-5108.	3.2	312
15	Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer. <i>European Urology</i> , 2014, 65, 534-542.	0.9	306
16	Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. <i>European Urology</i> , 2016, 70, 740-748.	0.9	292
17	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604.	0.6	279
18	Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. <i>Cancer Research</i> , 1993, 53, 3241-5.	0.4	271

#	ARTICLE	IF	CITATIONS
19	PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. <i>Journal of Immunotherapy</i> , 2012, 35, 169-178.	1.2	269
20	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011, 43, 1098-1103.	9.4	251
21	TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming. <i>Cancer Research</i> , 2006, 66, 10242-10246.	0.4	209
22	Genomic Markers in Prostate Cancer Decision Making. <i>European Urology</i> , 2018, 73, 572-582.	0.9	201
23	The use of PCA3 in the diagnosis of prostate cancer. <i>Nature Reviews Urology</i> , 2009, 6, 255-261.	1.9	198
24	MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. <i>Oncogene</i> , 2013, 32, 277-285.	2.6	198
25	Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3061-3070.	3.2	193
26	Strict regulation of CAIXG250/MN by HIF-1 α in clear cell renal cell carcinoma. <i>Oncogene</i> , 2004, 23, 5624-5631.	2.6	177
27	The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance. <i>Clinical Cancer Research</i> , 2007, 13, 939-943.	3.2	176
28	Canine prostate carcinoma: epidemiological evidence of an increased risk in castrated dogs. <i>Molecular and Cellular Endocrinology</i> , 2002, 197, 251-255.	1.6	167
29	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015, 68, 1033-1044.	0.9	166
30	Intermediate Cells in Human Prostate Epithelium Are Enriched in Proliferative Inflammatory Atrophy. <i>American Journal of Pathology</i> , 2003, 162, 1529-1537.	1.9	163
31	Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. <i>Prostate</i> , 1988, 13, 25-38.	1.2	162
32	Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>European Urology</i> , 2009, 56, 659-668.	0.9	161
33	Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. <i>Urology</i> , 2005, 66, 64-74.	0.5	158
34	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS. , 1996, 180, 295-299.		153
35	Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. <i>Cancer Research</i> , 1996, 56, 4154-8.	0.4	152
36	Demonstration of Intermediate Cells during Human Prostate Epithelial Differentiation In Situ and In Vitro Using Triple-Staining Confocal Scanning Microscopy. <i>Laboratory Investigation</i> , 2000, 80, 1251-1258.	1.7	150

#	ARTICLE	IF	CITATIONS
37	Molecular Genetics and Epidemiology of Prostate Carcinoma. <i>Endocrine Reviews</i> , 1999, 20, 22-45.	8.9	149
38	Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. <i>European Urology</i> , 2011, 60, 1045-1054.	0.9	148
39	Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. <i>Prostate</i> , 2010, 70, 10-16.	1.2	144
40	fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas.. <i>Journal of Clinical Investigation</i> , 1987, 80, 1545-1549.	3.9	143
41	Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. <i>Cancer Research</i> , 1992, 52, 6182-7.	0.4	143
42	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. <i>Science Translational Medicine</i> , 2010, 2, 62ra92.	5.8	140
43	Cellular and molecular biology of the prostate: stem cell biology. <i>Urology</i> , 2003, 62, 11-20.	0.5	134
44	New targets for therapy in prostate cancer: differential display code 3 (DD3PCA3), a highly prostate cancer-specific gene. <i>Urology</i> , 2003, 62, 34-43.	0.5	133
45	Decreased expression of E-cadherin in the progression of rat prostatic cancer. <i>Cancer Research</i> , 1992, 52, 2916-22.	0.4	133
46	The Progression of Benign Prostatic Hyperplasia: Examining the Evidence and Determining the Risk. <i>European Urology</i> , 2001, 39, 390-399.	0.9	125
47	Role of E Boxes in the Repression of E-Cadherin Expression. <i>Biochemical and Biophysical Research Communications</i> , 1997, 241, 453-458.	1.0	123
48	Complex cadherin expression in human prostate cancer cells. <i>International Journal of Cancer</i> , 2000, 85, 446-450.	2.3	122
49	Molecular Diagnosis of Prostate Cancer: <i>PCA3</i> and <i>TMPRSS2:ERG</i> Gene Fusion. <i>Journal of Urology</i> , 2012, 187, 795-801.	0.2	119
50	Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987, 84, 2421-2425.	3.3	117
51	Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. <i>European Urology</i> , 2013, 63, 201-209.	0.9	114
52	Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. <i>Cancer Research</i> , 1993, 53, 5512-6.	0.4	109
53	Stem Cell Characteristics in Prostate Cancer Cell Lines. <i>European Urology</i> , 2010, 57, 246-255.	0.9	104
54	Clinical use of novel urine and blood based prostate cancer biomarkers: A review. <i>Clinical Biochemistry</i> , 2014, 47, 889-896.	0.8	104

#	ARTICLE	IF	CITATIONS
55	Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. <i>American Journal of Pathology</i> , 2011, 178, 525-536.	1.9	102
56	Steroidogenic Enzymes and Stem Cell Markers Are Upregulated during Androgen Deprivation in Prostate Cancer. <i>Molecular Medicine</i> , 2011, 17, 657-664.	1.9	102
57	Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 12-19.	2.0	102
58	Molecular cloning and characterization of the human E-cadherin cDNA. <i>Molecular Biology Reports</i> , 1993, 17, 123-128.	1.0	100
59	Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. <i>Molecular Biology Reports</i> , 1986, 11, 117-125.	1.0	96
60	Characterization of Human Prostate Cancer, Benign Prostatic Hyperplasia and Normal Prostate by in vitro ¹ H and ³¹ P Magnetic Resonance Spectroscopy. <i>Journal of Urology</i> , 1993, 150, 2019-2024.	0.2	95
61	Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes. <i>Journal of Urology</i> , 2014, 191, 1132-1138.	0.2	95
62	Identification of intermediate cell types by keratin expression in the developing human prostate. , 1998, 34, 292-301.		94
63	Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study. <i>BMC Cancer</i> , 2005, 5, 57.	1.1	94
64	Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 117, 215-225.	1.3	94
65	EFFECT OF HYPERTHERMIA ON THE CYTOTOXICITY OF 4 CHEMOTHERAPEUTIC AGENTS CURRENTLY USED FOR THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER: AN IN VITRO STUDY. <i>Journal of Urology</i> , 2005, 173, 1375-1380.	0.2	92
66	The Role of Genetic Markers in the Management of Prostate Cancer. <i>European Urology</i> , 2012, 62, 577-587.	0.9	92
67	Expression of basal cell keratins in human prostate cancer metastases and cell lines. <i>Journal of Pathology</i> , 2001, 195, 563-570.	2.1	91
68	hTERT-Immortalized Prostate Epithelial and Stromal-Derived Cells: an Authentic In vitro Model for Differentiation and Carcinogenesis. <i>Cancer Research</i> , 2006, 66, 3531-3540.	0.4	90
69	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	5.1	90
70	The Mechanoreceptor TRPV4 is Localized in Adherence Junctions of the Human Bladder Urothelium: A Morphological Study. <i>Journal of Urology</i> , 2011, 186, 1121-1127.	0.2	89
71	Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. <i>Cancer Research</i> , 1991, 51, 606-11.	0.4	88
72	Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2000, 10, 153-159.	1.1	87

#	ARTICLE	IF	CITATIONS
73	In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. <i>Prostate</i> , 2009, 69, 1683-1693.	1.2	85
74	Noncoding RNAs as Novel Biomarkers in Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-17.	0.9	83
75	Relation between aberrant β -catenin expression and loss of E-cadherin function in prostate cancer. , 1997, 74, 374-377.		82
76	Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence. <i>Urology</i> , 2001, 58, 367-371.	0.5	82
77	Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications. <i>Cancer and Metastasis Reviews</i> , 1993, 12, 29-37.	2.7	81
78	Epithelial cell differentiation in the human prostate epithelium: Implications for the pathogenesis and therapy of prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 3-10.	2.0	81
79	Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. <i>Prostate</i> , 2008, 68, 1215-1222.	1.2	79
80	Urinary biomarkers for prostate cancer: a review. <i>Asian Journal of Andrology</i> , 2013, 15, 333-339.	0.8	74
81	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1369-1380.	1.6	74
82	Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy. <i>Journal of Urology</i> , 2019, 202, 256-263.	0.2	74
83	SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 alpha-REDUCTASE ISOZYME ENZYMATIC ACTIVITY IN THE HUMAN PROSTATE. <i>Journal of Urology</i> , 1999, 161, 332-337.	0.2	73
84	Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer. <i>Molecular Medicine</i> , 2012, 18, 1449-1455.	1.9	70
85	Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. <i>Carcinogenesis</i> , 2009, 30, 698-705.	1.3	68
86	Transcriptional Regulation of the Human E-Cadherin Gene in Human Prostate Cancer Cell Lines: Characterization of the Human E-Cadherin Gene Promoter. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 1284-1290.	1.0	67
87	Bladder Wash Cytology, Quantitative Cytology, and the Qualitative BTA Test in Patients with Superficial Bladder Cancer. <i>Urology</i> , 1998, 51, 44-50.	0.5	67
88	Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. <i>International Journal of Cancer</i> , 2000, 87, 217-220.	2.3	67
89	A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016, 64, 127-136.	1.3	67
90	Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and genetic sequences encoding a receptor-like protein. <i>EMBO Journal</i> , 1986, 5, 2197-202.	3.5	67

#	ARTICLE	IF	CITATIONS
91	The transcription factor Net regulates the angiogenic switch. <i>Genes and Development</i> , 2003, 17, 2283-2297.	2.7	63
92	Rapid microwave-stimulated fixation of entire prostatectomy specimens. , 1997, 183, 369-375.		62
93	A rabbit model to tissue engineer the bladder. <i>Biomaterials</i> , 2004, 25, 1657-1661.	5.7	62
94	The influence of high-energy shock waves on the development of metastases. <i>Ultrasound in Medicine and Biology</i> , 1996, 22, 339-344.	0.7	61
95	A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. <i>Prostate</i> , 2017, 77, 1401-1407.	1.2	61
96	Intermediate cells in normal and malignant prostate epithelium express c-MET: Implications for prostate cancer invasion. <i>Prostate</i> , 2002, 51, 98-107.	1.2	59
97	Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. <i>International Journal of Cancer</i> , 2002, 100, 683-685.	2.3	58
98	The Distribution and Function of Chondroitin Sulfate and Other Sulfated Glycosaminoglycans in the Human Bladder and Their Contribution to the Protective Bladder Barrier. <i>Journal of Urology</i> , 2013, 189, 336-342.	0.2	58
99	Models for studying benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2000, 3, 28-33.	2.0	57
100	The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. <i>BJU International</i> , 2010, 106, 1143-1147.	1.3	57
101	A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. <i>British Journal of Cancer</i> , 1996, 74, 573-578.	2.9	56
102	Smoothelin Expression Characteristics: Development of a Smooth Muscle Cell in vitro System and Identification of a Vascular Variant.. <i>Cell Structure and Function</i> , 1997, 22, 65-72.	0.5	56
103	Coordinate Recruitment of E-Cadherin and ALCAM to Cell-Cell Contacts by β -Catenin. <i>Biochemical and Biophysical Research Communications</i> , 2000, 267, 870-874.	1.0	55
104	miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting <i>ADAM9</i> and <i>TGFBR2</i> . <i>Cancer Research</i> , 2017, 77, 2008-2017.	0.4	55
105	Quantitative Light Microscopy in Urological Oncology. <i>Journal of Urology</i> , 1992, 148, 1-13.	0.2	54
106	The prognostic value of E-cadherin and the cadherin-associated molecules β -catenin and p120 ^{cas} in prostate cancer specific survival: A long-term follow-up study. <i>Prostate</i> , 2007, 67, 1432-1438.	1.2	54
107	In Vivo Effects of High Energy Shock Waves on Urological Tumors: An Evaluation of Treatment Modalities. <i>Journal of Urology</i> , 1990, 144, 785-789.	0.2	53
108	Molecular analysis of multifocal prostate cancer lesions. , 1999, 188, 271-277.		53

#	ARTICLE	IF	CITATIONS
109	Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. <i>BJU International</i> , 2001, 88, 35-42.	1.3	53
110	Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 101-109.	2.0	51
111	Molecular PCA3 diagnostics on prostatic fluid. <i>Prostate</i> , 2007, 67, 881-887.	1.2	49
112	The structure of the human c-fes/fps proto-oncogene. <i>EMBO Journal</i> , 1985, 4, 2897-903.	3.5	49
113	Liquid biopsy in bladder cancer: State of the art and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103577.	2.0	49
114	The in vitro effect of electromagnetically generated shock waves (Lithostar) on the Dunning R3327 PAT-2 rat prostatic cancer cell-line. <i>Urological Research</i> , 1989, 17, 13-19.	1.5	48
115	Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. , 1999, 82, 70-76.		48
116	Innovations in Serum and Urine Markers in Prostate Cancer. <i>European Urology</i> , 2005, 48, 1031-1041.	0.9	48
117	Applicability of biomarkers in the early diagnosis of prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 513-526.	1.5	47
118	Differential expression of <i>PCA3</i> and its overlapping <i>PRUNE2</i> transcript in prostate cancer. <i>Prostate</i> , 2010, 70, 70-78.	1.2	47
119	Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. <i>Prostate</i> , 2013, 73, 113-120.	1.2	47
120	Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 483-492.	1.4	47
121	Complex cadherin expression in renal cell carcinoma. <i>Cancer Research</i> , 1996, 56, 3234-7.	0.4	47
122	The Genes for the Calcium-Dependent Cell Adhesion Molecules P- and E-Cadherin Are Tandemly Arranged in the Human Genome. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 1291-1294.	1.0	46
123	Molecular markers for prostate cancer. <i>Cancer Letters</i> , 2007, 249, 5-13.	3.2	46
124	Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-“positive salivary duct carcinoma. <i>European Journal of Cancer</i> , 2019, 110, 62-70.	1.3	46
125	p53 mutations have no additional prognostic value over stage in bladder cancer. <i>British Journal of Cancer</i> , 1994, 70, 496-500.	2.9	45
126	Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo. , 1997, 32, 196-204.		45

#	ARTICLE	IF	CITATIONS
127	Urinary NMP22 TM and Karyometry in the Diagnosis and Follow-Up of Patients with Superficial Bladder Cancer. <i>European Urology</i> , 1998, 33, 387-391.	0.9	45
128	Rabbit Urethra Replacement with a Defined Biomatrix or Small Intestinal Submucosa. <i>European Urology</i> , 2003, 44, 266-271.	0.9	45
129	Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics – a decision analytical model. <i>BJU International</i> , 2017, 120, 659-665.	1.3	45
130	⁶⁸ Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. <i>Theranostics</i> , 2020, 10, 2273-2283.	4.6	45
131	Introduction: prostate cancer: from basic science to clinical application?. <i>Urology</i> , 2003, 62, 1-2.	0.5	44
132	Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in dutch prostate cancer patients. <i>Prostate</i> , 2011, 71, 415-420.	1.2	44
133	IS INCREASED CAG REPEAT LENGTH IN THE ANDROGEN RECEPTOR GENE A RISK FACTOR FOR MALE SUBFERTILITY?. <i>Journal of Urology</i> , 2002, 167, 621-623.	0.2	43
134	The role of HOXC6 in prostate cancer development. <i>Prostate</i> , 2015, 75, 1868-1876.	1.2	43
135	Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. <i>Anticancer Research</i> , 2003, 23, 3327-31.	0.5	43
136	Intravesical Gemcitabine: A Phase 1 and Pharmacokinetic Study. <i>European Urology</i> , 2004, 45, 182-186.	0.9	42
137	p16 mutations/deletions are not frequent events in prostate cancer. <i>British Journal of Cancer</i> , 1996, 74, 120-122.	2.9	41
138	Cadherin-11 is Expressed in Detrusor Smooth Muscle Cells and Myofibroblasts of Normal Human Bladder. <i>European Urology</i> , 2007, 52, 1213-1222.	0.9	41
139	Testosterone Measurement in Patients with Prostate Cancer. <i>European Urology</i> , 2010, 58, 65-74.	0.9	41
140	Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. <i>European Journal of Human Genetics</i> , 2011, 19, 118-120.	1.4	41
141	Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 336-342.	1.2	41
142	Decreased expression of β -catenin is associated with poor prognosis of patients with localized renal cell carcinoma. , 1997, 74, 523-528.		40
143	The Bard ^{reg} BTA Test: Its Mode of Action, Sensitivity and Specificity, Compared to Cytology of Voided Urine, in the Diagnosis of Superficial Bladder Cancer. <i>European Urology</i> , 1998, 34, 99-106.	0.9	40
144	The Effect of Hyperthermia on Mitomycin-C Induced Cytotoxicity in Four Human Bladder Cancer Cell Lines. <i>European Urology</i> , 2004, 46, 670-674.	0.9	40

#	ARTICLE	IF	CITATIONS
145	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1110-1119.	2.0	40
146	Cytotoxic Effects of High Energy Shock Waves in different in Vitro Models: Influence of the Experimental Set-Up. <i>Journal of Urology</i> , 1991, 145, 171-175.	0.2	39
147	Antitumoral Effects of Liarozole in Androgen-Dependent and Independent R3327-Dunning Prostate Adenocarcinomas. <i>Journal of Urology</i> , 1994, 151, 217-222.	0.2	39
148	The role of cell adhesion molecules and proteases in tumor invasion and metastasis. <i>World Journal of Urology</i> , 1996, 14, 151-6.	1.2	39
149	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives. <i>Prostate</i> , 1998, 36, 62-73.	1.2	39
150	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , 2007, 8, 84.	1.2	39
151	Human Papilloma Virus DNA and p53 Mutation Analysis on Bladder Washes in Relation to Clinical Outcome of Bladder Cancer. <i>European Urology</i> , 2007, 52, 464-469.	0.9	39
152	Urine cell-based DNA methylation classifier for monitoring bladder cancer. <i>Clinical Epigenetics</i> , 2018, 10, 71.	1.8	39
153	Quanticyt: Karyometric analysis of bladder washing for patients with superficial bladder cancer. <i>Urology</i> , 1996, 48, 357-364.	0.5	38
154	JC Virus Strains Indigenous to Northeastern Siberians and Canadian Inuits Are Unique But Evolutionally Related to Those Distributed Throughout Europe and Mediterranean Areas. <i>Journal of Molecular Evolution</i> , 2002, 55, 322-335.	0.8	37
155	Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. <i>BJU International</i> , 2004, 93, 27-29.	1.3	37
156	Differential regulation of human α 1-adrenoceptor subtypes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1999, 359, 439-446.	1.4	36
157	Antitumor activity of the polyamine analog N1,N11-diethylnorspermine against human prostate carcinoma cells. <i>Prostate</i> , 2000, 44, 313-321.	1.2	36
158	Prognostic Value of p53 for High Risk Superficial Bladder Cancer With Long-Term Followup. <i>Journal of Urology</i> , 2007, 177, 80-83.	0.2	36
159	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 219-230.	1.5	36
160	Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy. <i>International Journal of Cancer</i> , 2010, 127, 2542-2553.	2.3	35
161	Isolation and Characterization of the Promoter of the Human Prostate Cancer-specific DD3 Gene. <i>Journal of Biological Chemistry</i> , 2000, 275, 37496-37503.	1.6	34
162	Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. <i>Molecular and Cellular Endocrinology</i> , 2002, 197, 153-165.	1.6	34

#	ARTICLE	IF	CITATIONS
163	Structure of the feline c-fes/fps proto-oncogene: genesis of a retroviral oncogene. <i>Journal of Virology</i> , 1987, 61, 2009-2016.	1.5	34
164	Effects of high-energy shock waves combined with biological response modifiers in different human kidney cancer xenografts. <i>Ultrasound in Medicine and Biology</i> , 1991, 17, 391-399.	0.7	33
165	Mammary growth hormone and tumorigenesis – lessons from the dog. <i>Veterinary Quarterly</i> , 1999, 21, 111-115.	3.0	33
166	The Prognostic Value of E-Cadherin, β -1, β -2, and β -3-Catenin in Urothelial Cancer of the Upper Urinary Tract. <i>European Urology</i> , 2006, 49, 839-845.	0.9	32
167	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 89, 102069.	3.4	32
168	Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. <i>Cancer Research</i> , 1988, 48, 2042-6.	0.4	32
169	Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation. <i>Advanced Science</i> , 2020, 7, 2001797.	5.6	31
170	Prostate Cancer Liquid Biopsy Biomarkers – Clinical Utility in Diagnosis and Prognosis. <i>Cancers</i> , 2021, 13, 3373.	1.7	31
171	H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection. <i>Prostate</i> , 1991, 18, 163-172.	1.2	30
172	Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. <i>Prostate</i> , 2000, 44, 40-48.	1.2	30
173	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. <i>Prostate</i> , 2012, 72, 789-802.	1.2	30
174	A four-group urine risk classifier for predicting outcomes in patients with prostate cancer. <i>BJU International</i> , 2019, 124, 609-620.	1.3	30
175	Prognostic value of karyometric and clinical characteristics in renal cell carcinoma quantitative assessment of tumor heterogeneity. <i>Cancer</i> , 1993, 72, 2667-2674.	2.0	29
176	Alterations in Expression of Cadherin-6 and E-Cadherin during Kidney Development and in Renal Cell Carcinoma. <i>European Urology</i> , 2000, 38, 331-338.	0.9	29
177	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017, 8, 50804-50813.	0.8	29
178	Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases. <i>American Journal of Pathology</i> , 1991, 139, 1389-400.	1.9	29
179	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <i>Prostate</i> , 2014, 74, 1222-1230.	1.2	28
180	Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. <i>International Journal of Cancer</i> , 2020, 146, 3196-3206.	2.3	28

#	ARTICLE	IF	CITATIONS
181	Impact of <sc>DNA</sc> damage repair defects and aggressive variant features on response to carboplatinâ€based chemotherapy in metastatic castrationâ€resistant prostate cancer. International Journal of Cancer, 2021, 148, 385-395.	2.3	28
182	Expression and Molecular Characterization of the Growth Hormone Receptor in Canine Mammary Tissue and Mammary Tumors. Endocrinology, 1999, 140, 5907-5914.	1.4	27
183	Hypertension, antihypertensives and mutations in the Von Hippelâ€Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. Journal of Hypertension, 2005, 23, 1997-2004.	0.3	27
184	Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate International, 2014, 2, 105-113.	1.2	27
185	Structure and nucleotide sequence of the 5' region of the human and feline c-sis proto-oncogenes. Nucleic Acids Research, 1986, 14, 765-778.	6.5	26
186	Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology, 1997, 49, 652-657.	0.5	26
187	Neural network-based digitized cell image diagnosis of bladder wash cytology. Diagnostic Cytopathology, 2000, 23, 171-179.	0.5	26
188	The Long and Winding Road to FDA Approval of a Novel Prostate Cancer Test: Our Story. Clinical Chemistry, 2013, 59, 32-34.	1.5	26
189	Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. Oncogene, 2019, 38, 3696-3709.	2.6	26
190	A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. Oncotarget, 2017, 8, 10565-10579.	0.8	26
191	Intermediate filament expression and the progression of prostatic cancer as studied in the dunning R-3327 rat prostatic carcinoma system. Prostate, 1989, 14, 323-339.	1.2	25
192	Site-specific familial aggregation of prostate cancer. International Journal of Cancer, 2004, 109, 611-617.	2.3	25
193	Carotenoid and vitamin intake, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Cancer Causes and Control, 2008, 19, 125-134.	0.8	25
194	An integrated framework of personalized medicine: from individual genomes to participatory health care. Croatian Medical Journal, 2012, 53, 301-303.	0.2	25
195	Recurrent Gene Fusions in Prostate Cancer: Their Clinical Implications and Uses. Current Urology Reports, 2013, 14, 214-222.	1.0	25
196	Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. International Journal of Molecular Sciences, 2013, 14, 11347-11355.	1.8	25
197	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clinical Chemistry, 2020, 66, 842-851.	1.5	25
198	Genetic organization of the c-sistranscription unit. Nucleic Acids Research, 1987, 15, 959-970.	6.5	24

#	ARTICLE	IF	CITATIONS
199	HLA-class-I and-class-II expression on renal tumor xenografts and the relation to sensitivity for $\hat{\pm}$ -IFN, $\hat{\beta}$ -IFN and TNF. International Journal of Cancer, 1991, 48, 709-716.	2.3	24
200	Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. Prostate, 1991, 18, 331-344.	1.2	24
201	Molecular prognostic factors in bladder cancer. World Journal of Urology, 1994, 12, 84-8.	1.2	24
202	Homozygous deletions of p16INK4 occur frequently in bilharziasis-associated bladder cancer. , 1996, 68, 183-187.		24
203	Proliferative activity and branching morphogenesis in the human prostate: A closer look at pre- and postnatal prostate growth. Prostate, 2001, 49, 132-139.	1.2	24
204	Superficial and metachronous invasive bladder carcinomas are clonally related. International Journal of Cancer, 2001, 93, 699-702.	2.3	24
205	Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2009, 12, 241-246.	2.0	24
206	Urothelium update: how the bladder mucosa measures bladder filling. Acta Physiologica, 2017, 220, 201-217.	1.8	24
207	Tubulin Tyrosine Ligase Like 12, a TTL Family Member with SET- and TTL-Like Domains and Roles in Histone and Tubulin Modifications and Mitosis. PLoS ONE, 2012, 7, e51258.	1.1	24
208	A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters. Cancer Gene Therapy, 2001, 8, 927-935.	2.2	23
209	Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate, 2011, 71, 1701-1709.	1.2	23
210	Effects of high-energy shock waves combined with biological response modifiers or Adriamycin on a human kidney cancer xenograft. Urological Research, 1990, 18, 419-424.	1.5	22
211	Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. BJU International, 1998, 81, 844-851.	1.3	22
212	Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors. , 1999, 83, 591-595.		22
213	Canine Balloon and Signet-ring Cell Melanomas: a Histological and Immunohistochemical Characterization. Journal of Comparative Pathology, 2001, 125, 166-173.	0.1	22
214	Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. European Journal of Cancer, 2006, 42, 3219-3227.	1.3	22
215	Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. British Journal of Cancer, 2006, 95, 374-377.	2.9	22
216	Evaluation of urinary prostate cancer antigen-3 ($\langle \text{sc} \rangle \text{PCA} \langle / \text{sc} \rangle 3$) and $\langle \text{i} \rangle \langle \text{sc} \rangle \text{TMPRSS} \langle / \text{sc} \rangle 2$ $\langle \text{sc} \rangle \text{ERG} \langle / \text{sc} \rangle \langle \text{i} \rangle$ score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. BJU International, 2014, 114, 608-616.	1.3	22

#	ARTICLE	IF	CITATIONS
217	<scp>TRPV</scp>4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrier. <i>Acta Physiologica</i> , 2016, 218, 38-48.	1.8	22
218	Differential expression of vimentin in rat prostatic tumors. <i>Biochemical and Biophysical Research Communications</i> , 1992, 182, 1254-1259.	1.0	21
219	Liarozole, an antitumor drug, modulates cytokeratin expression in the dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. <i>Prostate</i> , 1995, 27, 129-140.	1.2	21
220	Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. <i>BJU International</i> , 2004, 93, 5-9.	1.3	21
221	The Predictive Value of p53, p27Kip1, and β -Catenin for Progression in Superficial Bladder Carcinoma. <i>European Urology</i> , 2006, 50, 76-82.	0.9	21
222	The prognostic value of E-cadherin, β -catenin and β -catenin in bladder cancer patients who underwent radical cystectomy. <i>International Journal of Urology</i> , 2007, 14, 789-794.	0.5	21
223	Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: A randomized, open-label, parallel-group pilot study. <i>Prostate</i> , 2009, 69, 1624-1634.	1.2	20
224	Molecular biomarkers to guide precision medicine in localized prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 791-804.	1.5	20
225	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. <i>Biomedical Chromatography</i> , 2017, 31, e3986.	0.8	20
226	Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis. <i>Cancers</i> , 2020, 12, 3790.	1.7	20
227	Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. <i>Invasion & Metastasis</i> , 1994, 14, 71-81.	0.5	20
228	Conventional bladder wash cytology performed by four experts versus quantitative image analysis. <i>Modern Pathology</i> , 1997, 10, 976-82.	2.9	20
229	Comparative analysis of the human and feline c-sis proto-oncogenes. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1985, 825, 140-147.	2.4	19
230	Early metabolic response to high energy shock waves in a human tumor kidney xenograft monitored by 31P magnetic resonance spectroscopy. <i>Ultrasound in Medicine and Biology</i> , 1991, 17, 791-801.	0.7	19
231	Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations. <i>Urological Research</i> , 1991, 19, 91-98.	1.5	19
232	Activated Leukocyte Cell Adhesion Molecule (ALCAM) Expression is Associated with a Poor Prognosis for Bladder Cancer Patients. <i>UroOncology</i> , 2003, 3, 121-129.	0.1	19
233	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. <i>BJU International</i> , 2008, 102, 177-182.	1.3	19
234	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. <i>European Urology Supplements</i> , 2010, 9, 675-691.	0.1	19

#	ARTICLE	IF	CITATIONS
235	Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. <i>Journal of Endocrinology</i> , 2002, 172, 489-495.	1.2	18
236	Engineered FGF-2 Expression Induces Glandular Epithelial Hyperplasia in the Murine Prostatic Dorsal Lobe. <i>European Urology</i> , 2004, 46, 126-132.	0.9	18
237	An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. <i>Prostate</i> , 2010, 70, 1524-1532.	1.2	18
238	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , 2020, 17, 351-362.	1.9	18
239	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 714-729.	1.5	18
240	Establishment and characterization of five new human renal tumor xenografts. <i>American Journal of Pathology</i> , 1992, 140, 483-95.	1.9	18
241	Immune response in hormonally-induced prostatic hyperplasia in the dog. <i>Veterinary Immunology and Immunopathology</i> , 2001, 78, 297-303.	0.5	17
242	Molecular prostate cancer pathology: Current issues and achievements. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 82-93.	1.4	17
243	DCSCRIPT: AR and VDR regulator lost upon transformation of prostate epithelial cells. <i>Prostate</i> , 2012, 72, 1708-1717.	1.2	17
244	Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen deprivation therapy. <i>BJU International</i> , 2017, 119, 74-81.	1.3	17
245	XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice. <i>PLoS ONE</i> , 2016, 11, e0159531.	1.1	17
246	In Vivo Antiproliferative Effects of Gamma-Interferon and Tumor Necrosis Factor Alpha in a Rat Renal Cell Carcinoma Model System. <i>Journal of Urology</i> , 1990, 143, 1247-1251.	0.2	16
247	Critical review of the models to study the biologic progression of bladder cancer. <i>Journal of Surgical Oncology</i> , 1992, 8, 274-278.	1.4	16
248	New Perspectives in the Treatment of Prostate Cancer. <i>European Urology</i> , 1997, 31, 20-23.	0.9	16
249	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2019, 30, e3.	0.6	16
250	Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8. , 1997, 31, 14-20.		15
251	A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 1999, 2, 277-281.	2.0	15
252	Tenascin Expression in Normal, Hyperplastic, Dysplastic and Neoplastic Canine Mammary Tissues. <i>Journal of Comparative Pathology</i> , 2002, 126, 1-8.	0.1	15

#	ARTICLE	IF	CITATIONS
253	Dutasteride and Enzalutamide Synergistically Suppress Prostate Tumor Cell Proliferation. <i>Journal of Urology</i> , 2015, 193, 1023-1029.	0.2	15
254	Major milestones in translational oncology. <i>BMC Medicine</i> , 2016, 14, 110.	2.3	15
255	Characterization of the feline c-abl proto-oncogene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1985, 824, 104-112.	2.4	14
256	In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines. <i>Prostate</i> , 1995, 26, 275-280.	1.2	14
257	Presence of carcinoma in situ and high 2c-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt. <i>Urology</i> , 2000, 55, 363-367.	0.5	14
258	Validation of molecular targets in prostate cancer. <i>BJU International</i> , 2005, 96, 23-29.	1.3	14
259	Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. <i>Therapeutic Advances in Urology</i> , 2014, 6, 245-252.	0.9	14
260	Direct dynamic measurement of intracellular and extracellular lactate in small-volume cell suspensions with ¹³ C hyperpolarised NMR. <i>NMR in Biomedicine</i> , 2015, 28, 1040-1048.	1.6	14
261	Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations. <i>Stem Cell Research and Therapy</i> , 2017, 8, 95.	2.4	14
262	Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 3789-3797.	1.2	14
263	Experssion of the human fes cellular oncogene in renal cell tumors. <i>Urological Research</i> , 1986, 14, 123-127.	1.5	13
264	Karyometry in recurrent superficial transitional cell tumors of the bladder. <i>Urological Research</i> , 1992, 20, 375-381.	1.5	13
265	The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. <i>Urological Research</i> , 1993, 21, 413-421.	1.5	13
266	Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 2006, 97, 852-855.	1.3	13
267	PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis. <i>Cancers</i> , 2010, 2, 1432-1440.	1.7	13
268	Involvement of orphan nuclear receptor COUP-TFII in cadherin-6 and cadherin-11 regulation: Implications in development and cancer. <i>Mechanisms of Development</i> , 2015, 136, 64-72.	1.7	13
269	Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. <i>Clinical Cancer Research</i> , 1996, 2, 1055-61.	3.2	13
270	Identification and partial characterization of two steroid 5 α -reductase isozymes in the canine prostate. , 1998, 34, 222-230.		12

#	ARTICLE	IF	CITATIONS
271	Branching Activity in the Human Prostate: A Closer Look at the Structure of Small Glandular Buds. <i>European Urology</i> , 2001, 39, 222-231.	0.9	12
272	Alcohol Dehydrogenase Type 3 (ADH3) and the Risk of Bladder Cancer. <i>European Urology</i> , 2001, 40, 509-514.	0.9	12
273	Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Pigs. <i>European Urology</i> , 2003, 44, 615-619.	0.9	12
274	Allelic imbalance in hereditary and sporadic prostate cancer. <i>Prostate</i> , 2003, 54, 50-57.	1.2	12
275	Molecular Diagnostics in Prostate Cancer. <i>EAU Update Series</i> , 2005, 3, 200-213.	0.5	12
276	Inflammation in the Pathophysiology of Benign Prostatic Hypertrophy. <i>European Urology Supplements</i> , 2015, 14, e1455-e1458.	0.1	12
277	In vitro antiproliferative efficacy of Interferon-alpha, gamma and Tumor Necrosis Factor on two human renal tumor xenografts. <i>Urological Research</i> , 1988, 16, 309-314.	1.5	11
278	Oncogene expression in prostate cancer. <i>World Journal of Urology</i> , 1991, 9, 58-63.	1.2	11
279	Biological effects of high energy shock waves in mouse skeletal muscle: Correlation between 31P magnetic resonance spectroscopic and microscopic alterations. <i>Ultrasound in Medicine and Biology</i> , 1993, 19, 399-409.	0.7	11
280	The Androgen Cascade in Ageing Men: Blessing or Curse?. <i>European Urology Supplements</i> , 2003, 2, 8-12.	0.1	11
281	Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines. <i>Oncology Reports</i> , 2004, 11, 357.	1.2	11
282	Future opportunities for the diagnosis and treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, S8-S13.	2.0	11
283	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 222-229.	1.0	11
284	Improving the barrier function of damaged cultured urothelium using chondroitin sulfate. <i>Neurourology and Urodynamics</i> , 2020, 39, 558-564.	0.8	11
285	How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?. <i>European Urology Oncology</i> , 2022, 5, 135-137.	2.6	11
286	Growth hormone induces tyrosyl phosphorylation of the transcription factors Stat5a and Stat5b in CMT-U335 canine mammary tumor cells. <i>Domestic Animal Endocrinology</i> , 2001, 20, 123-135.	0.8	10
287	Molecular aspects of hormone-independent prostate cancer. <i>BJU International</i> , 2007, 100, 52-55.	1.3	10
288	The Role of PCA3 Testing in Patients with a Raised Prostate-Specific Antigen Level After Greenlight Photoselective Vaporization of the Prostate. <i>Journal of Endourology</i> , 2010, 24, 1821-1824.	1.1	10

#	ARTICLE	IF	CITATIONS
289	Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. <i>Cancers</i> , 2021, 13, 3527.	1.7	10
290	Antitumor Effects of Bacillus Calmette- Guerin in a Syngeneic Rat Bladder Tumor Model System, RBT323. <i>Journal of Urology</i> , 1993, 149, 179-182.	0.2	9
291	The effects of successive high-energy shock-wave tumor administration on tumor blood flow. <i>Ultrasound in Medicine and Biology</i> , 1995, 21, 243-248.	0.7	9
292	LOSS OF CHROMOSOME 9 IN TISSUE SECTIONS OF TRANSITIONAL CELL CARCINOMAS AS DETECTED BY INTERPHASE CYTOGENETICS. A COMPARISON WITH RFLP ANALYSIS. , 1996, 179, 169-176.		9
293	Differential expression of ferritin Heavy chain in a rat transitional cell carcinoma progression model. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1997, 1360, 39-44.	1.8	9
294	Partial sequencing and tissue distribution of the canine isoforms of steroid 5?-Reductase type I and type II. <i>Prostate</i> , 2000, 44, 233-239.	1.2	9
295	Consecutive quantitative cytology in bladder cancer. <i>Urology</i> , 2000, 56, 584-588.	0.5	9
296	Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. <i>Urology</i> , 2002, 60, 357-362.	0.5	9
297	Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 273-283.	1.5	9
298	Androgen Receptor Mediated Growth of Prostate (Cancer). <i>European Urology Supplements</i> , 2005, 4, 4-11.	0.1	9
299	Alcohol Consumption and Mutations or Promoter Hypermethylation of the <i>von Hippel-Lindau</i> Gene in Renal Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3543-3550.	1.1	9
300	Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers. <i>Prostate Cancer</i> , 2012, 2012, 1-7.	0.4	9
301	High-resolutionERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. <i>BJU International</i> , 2013, 111, 836-842.	1.3	9
302	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021, 15, 2453-2465.	2.1	9
303	Effect of alpha- and gamma-Interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro. <i>Journal of Surgical Oncology</i> , 1988, 4, 195-198.	1.4	8
304	Magnetic resonance spectroscopy detects metabolic differences between seven dunning rat prostate tumor sublines with different biological behavior. <i>Prostate</i> , 1994, 25, 19-28.	1.2	8
305	MULTIFOCAL TRANSITIONAL CELL CANCER AND p53 MUTATION ANALYSIS. <i>Journal of Urology</i> , 1998, 160, 124-125.	0.2	8
306	Comparative Analysis of p53 Mutations in Bladder Washings and Histologic Specimens. <i>American Journal of Clinical Pathology</i> , 1998, 110, 647-652.	0.4	8

#	ARTICLE	IF	CITATIONS
307	A New, Straightforward Ex Vivo Organoid Bladder Mucosal Model for Preclinical Research. <i>Journal of Urology</i> , 2013, 190, 341-349.	0.2	8
308	The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer. <i>European Urology Focus</i> , 2015, 1, 99-108.	1.6	8
309	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e19-202.e28.	0.8	8
310	TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study showing TRPV1 related adaptations in the TRPV4 knockout mouse. <i>Pflügers Archiv European Journal of Physiology</i> , 2016, 468, 1741-1749.	1.3	8
311	Validation of a β -tubulin mRNA urine test for the detection of β -tubulin prostate cancer in an opportunistic screening population. <i>Prostate</i> , 2020, 80, 500-507.	1.2	8
312	Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene. <i>Gene</i> , 1985, 35, 33-43.	1.0	7
313	DETECTION OF ABNORMAL E-CADHERIN EXPRESSION BY SIMULATED PROSTATE BIOPSY. <i>Journal of Urology</i> , 1998, 160, 1368-1372.	0.2	7
314	Lower incidence of urothelial cell carcinoma due to the concept of a clonal origin. <i>European Journal of Cancer</i> , 2000, 36, 2385-2389.	1.3	7
315	CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. <i>International Journal of Cancer</i> , 2005, 116, 282-284.	2.3	7
316	Prostate cancer susceptibility genes on 8p21 \rightarrow 23 in a Dutch population. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 248-253.	2.0	7
317	Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models. <i>Cancer Gene Therapy</i> , 2022, 29, 793-802.	2.2	7
318	Delivery of antisense oligonucleotides for splice \rightarrow correction of androgen receptor pre \rightarrow mRNA in castration \rightarrow resistant prostate cancer models using cell \rightarrow penetrating peptides. <i>Prostate</i> , 2022, 82, 657-665.	1.2	7
319	Inhibition of Rat Bladder Tumor (Rbt323) Growth by Tumor Necrosis Factor Alpha and Interferon-Gamma in Vivo. <i>Journal of Urology</i> , 1992, 148, 458-462.	0.2	6
320	Treatment options in hormone resistant prostate cancer. <i>Annals of Oncology</i> , 2002, 13, 95-102.	0.6	6
321	Reply to Juan Morote \rightarrow 's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659 \rightarrow 68. <i>European Urology</i> , 2010, 57, e2-e3.	0.9	6
322	An Update of the Interstitial Cell Compartment in the Normal Human Bladder. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	6
323	Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer. <i>Translational Medicine Communications</i> , 2017, 2, .	0.5	6
324	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS. , 1996, 180, 295.		6

#	ARTICLE	IF	CITATIONS
325	Image analysis in superficial transitional cell carcinoma of the bladder. <i>Seminars in Urology</i> , 1993, 11, 164-70.	0.4	6
326	Effects of high energy shock waves on tumor blood flow and metabolism: $^{31}\text{P}/^1\text{H}/^2\text{H}$ nuclear magnetic resonance study. <i>NMR in Biomedicine</i> , 1994, 7, 319-326.	1.6	5
327	High Energy Shock Waves Induced Increase in the Local Concentration of Systemically Given TNF- α . <i>Journal of Urology</i> , 1994, 152, 2164-2166.	0.2	5
328	Transient tenascin enhancement is an early event after androgen ablation in rat prostate. <i>Urological Research</i> , 1999, 27, 9-15.	1.5	5
329	Quantitative Cytology on Bladder Wash versus Voided Urine: A Comparison of Results. <i>European Urology</i> , 2006, 49, 1044-1050.	0.9	5
330	The need for a personalized approach for prostate cancer management. <i>BMC Medicine</i> , 2015, 13, 109.	2.3	5
331	Pyruvate-lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized $[1\text{-}^{13}\text{C}]$ pyruvate MRS and $[18\text{F}]$ FDG-PET. <i>NMR in Biomedicine</i> , 2020, 33, e4362.	1.6	5
332	Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder. <i>Molecular Oncology</i> , 2021, 15, 1882-1900.	2.1	5
333	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	1.7	5
334	Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice. <i>Urology Practice</i> , 2019, 6, 256-261.	0.2	5
335	A Novel Immunoenzymatic Technique to Demonstrate Multiple Antigens in Cells Based on Selective Destaining of Substrate Deposits and Its Application in Characterizing the Immunophenotype of Neuroendocrine Cells in the Human Prostate Epithelium. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 1998, 6, 69-76.	2.0	5
336	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 248-248.	0.8	5
337	Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2024357119.	3.3	5
338	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 907-916.	2.9	5
339	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 6279.	1.7	5
340	Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 583-589.	2.0	5
341	Oncogenes and urological malignancies: Implications for the future. <i>Urological Research</i> , 1988, 16, 333-339.	1.5	4
342	Automated image analysis for bladder cancer. <i>Urological Research</i> , 1998, 26, 1-5.	1.5	4

#	ARTICLE	IF	CITATIONS
343	Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. European Urology Supplements, 2008, 7, 460-476.	0.1	4
344	Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. Oral Oncology, 2020, 110, 105018.	0.8	4
345	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. Cancers, 2020, 12, 3756.	1.7	4
346	Complex cadherin expression in human prostate cancer cells. , 2000, 85, 446.		4
347	Review articles How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer. Central European Journal of Urology, 2012, 65, 110-112.	0.2	4
348	Expression of proto-oncogenes in xenografts of human renal cell carcinomas. Urological Research, 1987, 15, 349-353.	1.5	3
349	Increased expression of retroviral sequences in progression advanced rat prostatic tumors. Biochemical and Biophysical Research Communications, 1992, 182, 318-324.	1.0	3
350	Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. Prostate, 2001, 47, 14-20.	1.2	3
351	New Developments in the Pathobiology of Prostate Disease. European Urology Supplements, 2006, 5, 729-736.	0.1	3
352	IMPROVED PREDICTION OF PROSTATE BIOPSY OUTCOME USING PCA3, TMPRSS2:ERG GENE FUSIONS AND SERUM PSA. Journal of Urology, 2008, 179, 725-725.	0.2	3
353	Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time. European Urology Supplements, 2009, 8, 97-102.	0.1	3
354	TRANSMEMBRANE PROTEASE SERINE 2 IN PROSTATE CANCER. BJU International, 2010, 105, 1490-1492.	1.3	3
355	Alterations of the Myovesical Plexus of the Human Overactive Detrusor. BioMed Research International, 2014, 2014, 1-8.	0.9	3
356	Self-reported acne is not associated with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 941-945.	0.8	3
357	In-depth assessment of metastatic prostate cancer with high tumour mutational burden. Annals of Oncology, 2018, 29, viii274.	0.6	3
358	Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 721659.	1.3	3
359	Use of animal models in diagnosis and treatment of renal cell carcinoma. World Journal of Urology, 1991, 9, 192-197.	1.2	2
360	Molecular Cloning of an Alternative Human β -E-Catenin cDNA. Biochemical and Biophysical Research Communications, 1997, 237, 177-181.	1.0	2

#	ARTICLE	IF	CITATIONS
361	Cadherin Switching in Human Prostate Cancer Progression. Japanese Journal of Urology, 2000, 91, 92.	0.0	2
362	Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. European Urology, 2008, 54, 1438-1439.	0.9	2
363	PERFORMANCE ANALYSIS OF DIFFERENT PCA3 CUT-OFFS. Journal of Urology, 2008, 179, 705-705.	0.2	2
364	2104 PROSPECTIVE MULTICENTER EVALUATION OF PCA3 AND TMPRSS2-ERG GENE FUSIONS AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.2	2
365	Overexpression of the c-MET proto-oncogene in salivary duct carcinoma patients. Annals of Oncology, 2017, 28, v374.	0.6	2
366	The importance of targeting intracrinology in prostate cancer management. World Journal of Urology, 2019, 37, 751-757.	1.2	2
367	642TiP Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer. Annals of Oncology, 2021, 32, S671.	0.6	2
368	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Cancers, 2021, 13, 4660.	1.7	2
369	In Vitro Sensitivity of Three Human Renal Tumor Xenografts Towards Tumor Necrosis Factor and Alpha and Gamma Interferon. , 1989, , 30-38.		2
370	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5036-5036.	0.8	2
371	Oncogene expression in prostate cancer. Progress in Clinical and Biological Research, 1990, 357, 97-105.	0.2	2
372	Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma. Analytical Cellular Pathology, 1994, 7, 153-70.	2.1	2
373	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5051-5051.	0.8	2
374	Image analysis and grading of prostate adenocarcinoma. World Journal of Urology, 1991, 9, 86-94.	1.2	1
375	Identification of New Prostate Cancer Progression Markers by Differential Hybridization Analysis. European Urology, 1992, 21, 60-65.	0.9	1
376	Translational research approaches in studying lower urinary tract symptoms: current and future challenges. Urology, 2004, 63, 1-2.	0.5	1
377	Etiology and management of pelvic pain syndrome. Urology, 2004, 63, 74.	0.5	1
378	Prostate (Cancer) Stem Cells. , 2007, , 63-72.		1

#	ARTICLE	IF	CITATIONS
379	Editorial Comment on: Increased Expression of Tumor-Associated Trypsin Inhibitor, TATI, in Prostate Cancer and in Androgen-Independent 22Rv1 Cells. <i>European Urology</i> , 2007, 52, 1679.	0.9	1
380	DETECTION OF TMPRSS2-ERG FUSION TRANSCRIPTS AND PCA3 IN URINARY SEDIMENTS MAY IMPROVE DIAGNOSIS OF PROSTATE CANCER. <i>Journal of Urology</i> , 2008, 179, 685-685.	0.2	1
381	Editorial Comment on: Mutations in the AXIN1 Gene in Advanced Prostate Cancer. <i>European Urology</i> , 2009, 56, 494.	0.9	1
382	1036 THE UROTHELIAL CELL-LINE RT4 EXPRESSES A GLYCOSAMINOGLYCAN (GAG) LAYER ON ITS OUTER SURFACE; AN IN VITRO MODEL FOR THE BLADDER GAG-LAYER. <i>Journal of Urology</i> , 2010, 183, .	0.2	1
383	Adherence Junctions and Cadherin-11 in Normal and Overactive Human Detrusor Smooth Muscle Cells. <i>Journal of Urology</i> , 2011, 185, 1946-1951.	0.2	1
384	Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports. <i>BMC Urology</i> , 2019, 19, 124.	0.6	1
385	The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1688.	1.8	1
386	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS. , 1996, 180, 295.		1
387	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives. <i>Prostate</i> , 1998, 36, 62-73.	1.2	1
388	Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. , 2000, 44, 40.		1
389	PCA3. , 2009, , 233-241.		1
390	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 330-330.	0.8	1
391	Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 91-91.	0.8	1
392	New targets for molecular diagnosis of prostate cancer: beyond the era of PSA. <i>Central European Journal of Urology</i> , 2009, 62, 145-149.	0.2	1
393	Elevated HOXC6/DLX1 mRNA biomarker levels in urine to help select patients at increased risk for high-grade prostate cancer detection upon prostate biopsy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 31-31.	0.8	1
394	Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladder. <i>Progress in Clinical and Biological Research</i> , 1992, 378, 9-18.	0.2	1
395	Expression of Proto-Oncogenes in Xenografts of Human Renal Cell Carcinomas. <i>Journal of Urology</i> , 1987, 137, .	0.2	0
396	Differential Expression of Genes in Metastasizing and Non-Metastasizing Prostatic Tumor Cells. <i>Journal of Urology</i> , 1987, 137, .	0.2	0

#	ARTICLE	IF	CITATIONS
397	BASIC RESEARCH. International Journal of Urology, 1995, 2, 117-121.	0.5	0
398	Prognostic Factors in Prostate Cancer. , 1996, , 77-85.		0
399	Genetic and molecular markers in the prognosis of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 1998, 4, 139-144.	0.8	0
400	A NEW MARKER FOR INTERSTITIAL CELLS IN THE HUMAN BLADDER. Journal of Urology, 2008, 179, 538-538.	0.2	0
401	PROSTATE CANCER 3 (PCA3) REPRESENTS A CLINICALLY MEANINGFUL PREDICTOR OF PROSTATE CANCER AT REPEAT BIOPSY. Journal of Urology, 2008, 179, 724-725.	0.2	0
402	Reply to the letter to the editor: "Differential expression of <i>PCA3</i> and <i>BMCC1</i> in Prostate Cancer," by Lavin M.F., Clarke R. and R.A. Gardiner. Prostate, 2009, 69, 1715-1715.	1.2	0
403	FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST. Journal of Urology, 2009, 181, 814-814.	0.2	0
404	Reply to Tomasz Drewa's Letter to the Editor re: Minja J. Pfeiffer, Jack A. Schalken. Stem Cell Characteristics in Prostate Cancer Cell Lines. Eur Urol 2010;57:246-55. European Urology, 2010, 57, e27.	0.9	0
405	198 TRPV4 IN STRETCH SENSATION. TRPV4 IN THE UROTHELIUM OF HUMAN BLADDER, KIDNEY & URETER COLOCALIZES WITH ADHERENCE JUNCTIONS. Journal of Urology, 2010, 183, .	0.2	0
406	2124 PREDICTING PROSTATE BIOPSY OUTCOME IN A SCREENING SETTING. PSA, PCA3, A KALLIKREIN PANEL, THE RISKCALCULATOR OR A COMBINATION? ERSPC ROTTERDAM. Journal of Urology, 2010, 183, .	0.2	0
407	1616 RATIONAL BASIS FOR THE COMBINATION OF PCA3 AND TMPRSS2:ERG GENE FUSION IN PROSTATE CANCER DIAGNOSIS. Journal of Urology, 2011, 185, .	0.2	0
408	2320 INITIAL AND REPEAT PROSTATE BIOPSY: COMPARATIVE PERFORMANCE ANALYSIS OF PSA, %FPSA, PROSTATE VOLUME AND URINARY PCA3 INCLUDING DEVELOPMENT OF NOVEL PCA3 CUT-OFF THRESHOLDS. Journal of Urology, 2011, 185, .	0.2	0
409	987 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON SCORE ≥ 7) AT BIOPSY. Journal of Urology, 2011, 185, .	0.2	0
410	1573 EXPRESSION PROFILING OF INFLAMMATION RELATED GENES IN BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2011, 185, .	0.2	0
411	1907 CORRELATION OF PCA3 AND MRI WITH BIOPSY OUTCOME. Journal of Urology, 2011, 185, .	0.2	0
412	Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back. Advances in Urology, 2012, 2012, 1-2.	0.6	0
413	226 THE RATIONALE OF COMBINATION THERAPY TARGETING INTRATUMORAL STEROIDOGENESIS IN CASTRATION RESISTANT PROSTATE CANCER (CRPC). Journal of Urology, 2012, 187, .	0.2	0
414	257 TRPV4 IS INVOLVED IN CELL JUNCTION FORMATION IN THE UROGENITAL TRACT. AN ULTRASTRUCTURAL STUDY. Journal of Urology, 2012, 187, .	0.2	0

#	ARTICLE	IF	CITATIONS
415	824 SULPHATED GLYCOSAMINOGLYCANS (GAG'S) CONTRIBUTE TO THE BLADDER BARRIER. Journal of Urology, 2012, 187, .	0.2	0
416	1216 DEVELOPMENT OF NOVEL PCA3 CUT-OFFS FOR INITIAL AND REPEAT BIOPSY USING DIFFERENT STATISTICAL APPROACHES WITHIN A US- EUROPEAN MULTI INSTITUTIONAL COHORT. Journal of Urology, 2012, 187, .	0.2	0
417	1210 BIOPSY-SPECIFIC PCA3- BASED PROSTATE BIOPSY NOMOGRAMS ARE HIGHLY ACCURATE. Journal of Urology, 2012, 187, .	0.2	0
418	Next Generation Screening Tests. , 2013, , 347-354.		0
419	312 CAIX AND MCT4 SUPPRESSION DOWN-REGULATE THE CELL VIABILITY IN CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2013, 189, .	0.2	0
420	MP31-13 THE EXPRESSION AND FUNCTION OF FAM110A IN HUMAN PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
421	Contemporary approaches to prostate cancer management. Future Oncology, 2015, 11, 2735-2736.	1.1	0
422	MP53-04 IDENTIFICATION OF HIGH-GRADE PROSTATE CANCER USING URINE-BASED MOLECULAR BIOMARKERS COMBINED WITH CLINICAL RISK FACTORS. Journal of Urology, 2016, 195, .	0.2	0
423	MP02-02 MULTICENTER VALIDATION STUDY OF A MOLECULAR URINE TEST TO PREDICT HIGH-GRADE PROSTATE CANCER.. Journal of Urology, 2016, 195, .	0.2	0
424	Urine biomarker profiling contains structure and predicts prostate cancer hormone therapy relapse. European Journal of Cancer, 2016, 61, S204.	1.3	0
425	Biomarkers for Prostate Cancer. , 2017, , 77-96.		0
426	MP33-17 POTENTIAL ROLE OF A NOVEL URINARY BIOMARKER-BASED RISK SCORE TO SELECT PATIENTS FOR MULTIPARAMETRIC MRI FOR PROSTATE CANCER DETECTION.. Journal of Urology, 2017, 197, .	0.2	0
427	Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma. Annals of Oncology, 2017, 28, v373-v374.	0.6	0
428	MP46-11 EVALUATION OF TWO URINARY RNA BIOMARKER TESTS WITH AN EPIGENETIC DNA ASSAY FOR THE IDENTIFICATION OF MEN WITH HIGH-GRADE PROSTATE CANCER. Journal of Urology, 2018, 199, .	0.2	0
429	Long non-coding RNAs as prognostic biomarkers for castration-resistant prostate cancer. European Urology Supplements, 2018, 17, e2537.	0.1	0
430	Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma. Annals of Oncology, 2018, 29, viii385.	0.6	0
431	68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma and salivary duct carcinoma. Annals of Oncology, 2018, 29, viii481.	0.6	0
432	Combining multi-parametric M.R.I and an epigenetic biomarker assay improves patient prostate cancer risk profile. European Urology Supplements, 2018, 17, e2476.	0.1	0

#	ARTICLE	IF	CITATIONS
433	MP46-20 COST-EFFECTIVENESS OF SELECTMDX FOR PROSTATE CANCER IN FOUR EUROPEAN COUNTRIES: A MODELLING STUDY. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
434	Development and characterization of salivary gland cancer organoid cultures. <i>Annals of Oncology</i> , 2019, 30, v472-v473.	0.6	0
435	775P Whole blood transcriptomic profiling to predict response to immunotherapy in metastatic urothelial cancer. <i>Annals of Oncology</i> , 2020, 31, S596.	0.6	0
436	Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6071-6071.	0.8	0
437	Cell Adhesion Molecules in Genitourinary Cancer. , 2003, , 455-472.		0
438	Biomarkers for Prostate Cancer. , 2012, , 55-68.		0
439	Abstract 1112: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library. , 2012, , .		0
440	Molecular Identification of the Indolent Versus Lethal Tumor. , 2013, , 81-94.		0
441	Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems. , 1991, , 47-55.		0
442	Antitumor Effects of High-Energy Shock Waves are Potentiated by Doxorubicin and Biological Response Modifiers. , 1991, , 228-237.		0
443	Prediction of Cytokine-Therapy on Basis of Class-I and Class-II MHC Antigen Induction. , 1992, , 121-133.		0
444	Magnetic Resonance Spectroscopic Evaluation of the Effects of High-Energy Shock Waves Administered to a Human Kidney Cancer Xenograft. , 1993, , 34-39.		0
445	Antitumorale Wirkungen immuntherapeutischer Agenzien in vitro und in vivo in einem syngenem Tiermodell des Nierenzellkarzinoms. , 1993, , 62-71.		0
446	Genetische Schritte in Zusammenhang mit der Entstehung des Prostatakarzinoms. , 1993, , 151-165.		0
447	Therapeutic Applications of Monoclonal Antibodies in Combination with Cytokines in Renal Cell Carcinoma. , 1994, , 132-140.		0
448	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 329-329.	0.8	0
449	Abstract 3768: Targeting of epithelial-to-mesenchyme transition by a novel small molecule inhibitor attenuates prostate and breast cancer invasiveness and bone metastases. , 2016, , .		0
450	MP24-04â€¦A 2-GENE MRNA URINE TEST FOR DETECTION OF HIGH-GRADE PROSTATE CANCER PRIOR TO INITIAL PROSTATE BIOPSY. <i>Journal of Urology</i> , 2019, 201, .	0.2	0

#	ARTICLE	IF	CITATIONS
451	Abstract 349: Oncolytic reovirus variants induce direct oncolysis in human prostate cancer. , 2019, , .		0
452	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
453	PD53-04â€¦THE SELECTMDX URINARY-BIOMARKER TEST. Journal of Urology, 2020, 203, e1097-e1098.	0.2	0
454	First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. Journal of Clinical Oncology, 2022, 40, 40-40.	0.8	0
455	MP45-04â€¦SELECTMDX URINE TEST DIAGNOSE MEN WITH HIGH-GRADE PROSTATE CANCER. Journal of Urology, 2022, 207, .	0.2	0
456	Abstract 349: Oncolytic reovirus variants induce direct oncolysis in human prostate cancer. , 2019, , .		0
457	Molecular alterations associated with prostate cancer development. , 0, , .		0